Showing 3941-3950 of 5623 results for "".
- Envision University Sets Agenda for In-Person Spring 2023 Conferencehttps://modernod.com/news/envision-university-sets-agenda-for-in-person-spring-2023-conference/2481426/The agenda has been set for the Envision Conference West, which will be held in collaboration with UT Health Department of Occupational Therapy, March 30-April 1, 2023, at the Academic Learning and Teaching Center of UT Health in San Antonio, Texas. The Envision Conference is the only multid
- Belkin Vision’s New Glaucoma Laser Technology Now Available in Germanyhttps://modernod.com/news/belkin-visions-new-glaucoma-laser-technology-now-available-in-germany/2481425/Belkin Vision announced that its Direct SLT Eagle device, an automated, non-contact glaucoma laser treatment, is being used to treat glaucoma patients at The University Eye Clinic in Bochum, Germany. “The Eagle by Belkin Vision will be transformative for many of the esti
- Clearside Biomedical Announces Positive Data on CLS-AX OASIS Clinical Trial and Use of SCS Microinjectorhttps://modernod.com/news/clearside-biomedical-announces-positive-data-on-cls-ax-oasis-clinical-trial-and-use-of-scs-microinjector/2481423/Clearside Biomedical announced data from presentations delivered at the Angiogenesis, Exudation, and Degeneration 2023 meeting and The Macula Society 46th Annual Meeting. “The promising durability data from our OASIS clinical trial continues to garner si
- FDA Accepts Iveric Bio's NDA and Grants Priority Review for Geographic Atrophy Drug Candidatehttps://modernod.com/news/fda-accepts-iveric-bios-nda-and-grants-priority-review-for-geographic-atrophy-drug-candidate/2481418/Iveric bio announced that the FDA has completed its filing review and accepted the company’s new drug application (NDA) for avacincaptad pegol (ACP), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degen
- Brent Saunders Returns to Bausch + Lomb as CEO and Chair of the Board of Directorshttps://modernod.com/news/brent-saunders-returns-to-bausch-lomb-to-serve-as-ceo-and-chair-of-the-board-of-directors/2481411/After nearly a decade, pharma executive Brent Saunders is returning to Bausch + Lomb where he will serve as CEO and Chair of the Board of Directors, effective March 6, 2023. Mr. Saunders served as Bausch + Lomb's CEO from 2010 to 2013 before its sale to Valeant Pharmaceuti
- Visionix Launches Optovue Solix FullRange OCThttps://modernod.com/news/visionix-launches-optovue-solix-fullrange-oct/2481409/Visionix USA has introduced the Optovue Solix FullRange OCT in North America. Featuring 120kHz ultra-high-speed scanning, Optovue Solix FullRange OCT features anterior 18 x 6.25 scans, new posterior high-density scan patterns for more detail and better precision, int
- Ocular Therapeutix Announces Interim Data from the Ongoing US Phase 1 Trial Evaluating OTX-TKI for the Treatment of Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-interim-data-from-the-ongoing-us-phase-1-trial-evaluating-otx-tki-for-the-treatment-of-wet-amd/2481406/Ocular Therapeutix announced interim 10-month data from its US phase 1 clinical trial evaluating OTX-TKI, the company’s axitinib intravitreal hydrogel implant being developed for the treatment of wet age-related macular degeneration (AMD), diabetic retinopathy, and other retinal diseas
- Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis for Wet AMD Meets Primary Endpointhttps://modernod.com/news/opthea-phase-2b-trial-results-of-opt-302-in-combination-with-lucentis-for-wet-amd-meets-primary-endpoint/2481405/Opthea announced that the phase 2b study results of OPT-302, the company’s anti-VEGF-C/-D “trap” agent administered in combination with Lucentis (ranibizumab) for the treatment of wet age-related macular degeneration (AMD), met the prespecified primary efficacy endpoint.
- Novaliq Plans to File a Marketing Authorization Application for CyclASol in the EU for Dry Eye Diseasehttps://modernod.com/news/novaliq-plans-to-file-a-markting-authorization-application-for-cyclasol-in-the-eu-for-the-treatment-of-dry-eye-disease-in-july-2023/2481396/Novaliq announced its plans for filing a marketing authorization application (MAA) CyclASol (ciclosporin ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment of dry eye disease (DED), in the European Union. The Committee for Medicinal Products for H
- Omeros Receives $200 Million Milestone Payment from Raynerhttps://modernod.com/news/omeros-receives-200-million-milestone-payment-from-rayner/2481391/Omeros announced that Rayner has paid the $200 million milestone payment due to Omeros under the Asset Purchase Agreement, dated December 1, 2021, pursuant to which Omeros sold its ophthalmology product Omidria to Rayner in December of 2021. Omeros received